Rusk Rehabilitation Brooklyn at Sunset Park Family Health Center | NYU Langone Health
Rusk Rehabilitation Brooklyn at Sunset Park Family Health Center provides rehabilitative therapies to adults and children.
Rusk Rehabilitation Brooklyn at Sunset Terrace Family Health Center | NYU Langone Health
NYU Langone’s Rusk Rehabilitation Brooklyn at Sunset Terrace Family Health Center provides rehabilitation therapy to adults recovering from illness or injury.
Rusk Rehabilitation Doctors | NYU Langone Health
Find a doctor at the Rusk Rehabilitation at NYU Langone.
Rusk Rehabilitation Wellness Services | NYU Langone Health
The team at NYU Langone’s Rusk Rehabilitation offers wellness services such as acupuncture and massage to complement your treatment.
S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Br
In this study, the study team wants to find out if adding a medicine called durvalumab to the usual chemotherapy for breast cancer helps patients do better. The study team will compare two groups: one getting regular chemotherapy alone, and the other getting the same chemotherapy but with durvalumab at the same time. They are checking if patients stay free of breast cancer events, how well the treatments work, and if there are any side effects from treatment. Also, the study team is interested in how patients feel during and after treatment, especially looking at things like tiredness of a patient and overall physical health. The study team will also save some samples for future studies. The goal is to understand if this new approach can improve outcomes for patients with breast cancer.
S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET) A RANDOMIZED PHASE III STUDY
This study is for patients with early-stage triple-negative breast cancer (TNBC). The study team wants to compare two kinds of treatments, one with a drug called anthracycline and another without it, but both using another drug called pembrolizumab. The study team is checking if the treatment without anthracycline is just as effective as the one with it, especially in terms of how long patients stay free of cancer events. The study team is also looking at how patients feel during and after the treatment concerning side effects. Additionally, the study team is studying something called tumor-infiltrating lymphocytes (TILs) to make sure the treatment works for everyone. This part of the study will help the study team understand the outcomes based on the amount of TILs in the tumors. Overall, the goal is to find the most effective treatment with few side effects for patients with TNBC.
Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH SF Catheter with the TRUPULSE Generator for treatment of drug refractory symptomatic Paroxysmal Atrial Fibrillation (PAF)
This is a prospective, single arm, multi-center, clinical evaluation of the PF/RF ablation system (THERMOCOOL SMARTTOUCH™ SF (STSF) Catheter and TRUPULSE™ Generator) to demonstrate safety and effectiveness of the system for the treatment of Paroxysmal Atrial Fibrillation (PAF) comparing to corresponding performance goals.
Safety and Efficacy of Empagliflozin in Hemodialysis (SEED)
The purpose of this research study is to explore the safety and efficacy of a drug called empagliflozin (EMPA) in reducing kidney and cardiovascular events in patients on maintenance hemodialysis (HD).
Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure (ALLAY-HF)
The purpose of this study is to evaluate the safety and efficacy of the Alleviant ALV1 System in patients with chronic heart failure (HF) and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), who remain symptomatic despite appropriate guideline directed medical therapy (GDMT).
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective Randomized Trial
***THIS STUDY IS FOR CURRENT HOSPITALIZED PATIENTS ONLY*** The only drug approved by the United States Food and Drug Administration (US FDA) for treatment of aneurysmal subarachnoid hemorrhage (aSAH) is nimodipine. It is given to patients to lower the possibility of DCI and vasospasm and to improve the chances of recovery. In the U.S., nimodipine is given by mouth (orally) as 60 mg (two 30 mg capsules) taken every 4 hours for up to 21 consecutive days. Although nimodipine has been approved because it increases the chances of recovery from aSAH, nimodipine sometimes causes side effects, such as low blood pressure, which can be harmful. This study is testing an investigational (experimental) drug or study medication, GTX 104, which is a new form of nimodipine that is administered through an intravenous (IV) line. “Investigational” means the new formulation being tested has not been approved by the US FDA for sale as a prescription or over-the-counter medication. GTX 104 is being tested to determine if it can be approved for use in the US. The goal of this study is to deliver the nimodipine directly into your bloodstream to see if this way of giving the drug is as tolerable as the currently available oral nimodipine capsules. The safety of the investigational drug will also be studied.